Merck & Co’s Keytruda immunotherapy has produced mixed results in a phase 3 trial testing it in first-line extensive-stage small cell lung cancer (SCLC).
Spain's PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin in the US, which is being teed up for a launch in 2020.
AbbVie has axed its troubled lung cancer drug Rova-T, after another trial failure from the drug that is turning out to be an expensive flop, costing almost $10 billion so far.
The FDA has approved Merck's Keytruda (pembrolizumab) as a combination treatment for metastatic nonsquamous non-small cell lung cancer (NSCLC), after green-lighting Bristol-Myers Squibb’s (BMS)
Endeavor BioMedicines has completed a third round financing, raising an impressive $132.5 million to fund trials of its two clinical-stage drug candidates for pulmonary fi
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.